checkAd
    23andMe Holding Registered (A) Aktie
    0,5821
     
    USD
    -4,71 %
    -0,0288 USD
    Letzter Kurs 21:58:14 Nasdaq
    0,5813
     
    USD
    2.800 STK
    Geldkurs 21:58:14
    0,5880
     
    USD
    200 STK
    Briefkurs 21:58:14
    ISIN: US90138Q1085 · WKN: A3CSVR · SYM: ME · USA

    Neueste Nachrichten

    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
    14.05.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe to Report Q4 and Full Year FY2024 Financial Results
    09.05.24 · globenewswire · 23andMe Holding Registered (A)
    Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
    30.04.24 · Business Wire (engl.) · 23andMe Holding Registered (A)
    23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe announces CEO’s intention to pursue a potential take-private
    18.04.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
    05.04.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
    20.03.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
    19.03.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Launches New Genetic Reports on Common Forms of Cancer
    06.03.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
    05.03.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Reports Third Quarter Fiscal 2024 Financial Results
    07.02.24 · globenewswire · 23andMe Holding Registered (A)
    23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
    31.01.24 · globenewswire · 23andMe Holding Registered (A)